FDA panel considers easing restrictions on peptide therapies
7 verified3 unconfirmed
A Food and Drug Administration advisory panel began a two-day meeting on July 23 to review whether to allow compounding pharmacies to produce seven experimental peptide therapies. The compounds, including TB-500, BPC-157 and MOTs-C, have gained popularity for injury recovery, muscle growth and other wellness uses despite lacking large-scale human safety and efficacy trials. Health Secretary Robert F. Kennedy Jr. has advocated for lifting current restrictions, arguing that FDA-inspected facilities offer a safer alternative to unregulated gray-market suppliers. However, FDA scientists have recommended against the move, citing data that is primarily from animal studies and limited for humans. The panel will vote on recommendations for each peptide, but the FDA’s leadership will make the final decision. Proponents contend that the current restrictions have driven consumers to risky overseas sources, while critics say safety concerns remain unresolved.
What’s verified
The FDA advisory panel is meeting July 23-24 to consider regulatory changes for seven peptide therapies.
The peptides under review include BPC-157, TB-500 and MOTs-C.
The meeting addresses whether compounding pharmacies should be allowed to manufacture these peptides.
Health Secretary Robert F. Kennedy Jr. supports lifting restrictions, citing patient safety through regulated facilities.
FDA scientists recommend against allowing compounding, citing limited human data and reliance on preclinical animal studies.
The peptides have not undergone large-scale trials required for FDA drug approval.
The panel will vote on recommendations, but FDA leadership makes the final decision.
Not yet confirmed
One source lists additional peptides under consideration: KPV, Emideltide, Epitalon and Semax.
Neither source specifies how many of the seven peptides the panel is expected to recommend for compounding.
It remains unclear when the FDA will issue its final decision after the panel’s recommendations.
Key figures
Robert F. Kennedy Jr. – Health Secretary
FDA advisory committee members (including newly added temporary voting members from academic institutions, as noted in one source)
Sources: NPR, statnews.com
